Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
ConditionAndrogenetic Alopecia (AGA)
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorShanghai Zhongshan Hospital
About this trial
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:
• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.
Participants will:
* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.
Eligibility criteria
Qualifiers
Clinically diagnosed with androgenetic alopecia (AGA)
No pregnancy plans within the next 6 months
Disqualifiers
Patients who received systemic medications for hair loss within the past 2 months
Use of topical medication for hair loss within the past 2 weeks
Pregnancy or lactation
Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Trial design
Treatments tested in this trial
- Oral DHA + Topical minoxidil 5%
- Topical Minoxidil 5%
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov